title: Engineering effective T-cell based antitumor immunity.
abstract: The adoptive transfer of synthetic siRNA-mediatedcblb-depleted autologous CD8+T cells acts as a potent adjuvant for dendritic cell (DC) vaccination and provides a significant therapeutic benefit. Our proof-of-concept study validates the strategy of inhibiting CBLB as a rational approach to augment the effectiveness of adoptively transferred immune cells.
authors.affiliation: Department of Pharmacology and Genetics; Medical University Innsbruck; Innsbruck, Austria.
authors.forename: Thomas
authors.initials: T
authors.lastname: Gruber
authors.forename: Reinhard
authors.initials: R
authors.lastname: Hinterleitner
authors.forename: Christa
authors.initials: C
authors.lastname: Pfeifhofer-Obermair
authors.forename: Dominik
authors.initials: D
authors.lastname: Wolf
authors.forename: Gottfried
authors.initials: G
authors.lastname: Baier
keywords: RNA interference; cancer immunotherapy; cblb; engineered T cells; reinforced anti-tumor functions